Oussama ABCHIR

Dr. Oussama ABCHIR

Chemistry department, Hassan II University, Casablanca, Casablanca-Settat, Morocco
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2022 in Heliyon
Verified
Journal Article
Open access
HNHassan Nour
Hassan Nour
OSSAMA DAOUIOSSAMA DAOUI
OSSAMA DAOUI
OAOussama ABCHIR
Oussama ABCHIR
SESouad ElKhattabi
Souad ElKhattabi
SBSalah Belaidi
Salah Belaidi
SCSamir Chtita
Samir Chtita
Butyrylcholinesterase is an acetylcholine-degrading enzyme involved in the memorization process, which is becoming an interesting target for the symptomatic treatment of Alzheimer's disease. In the present investigation, the structure–activity relationship of a set of Liquiritigenin derivatives recently revealed to be Butyrylcholinesterase inhibitors was studied basing on comparative field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMISA). As a result, performant models with high predictive capability have been developed (CoMFA model: R2 = 0.91, Q2 = 0.62, R2pred = 0.85; CoMISA model: R2 = 0.92, Q2 = 0.59, R2pred = 0.83) and implemented to design new Liquiritigenin derivatives with improved activity. Besides, the affinity of the designed derivatives towards the active site of Butyrylcholinesterase, was confirmed by molecular docking and molecular dynamics studies. Moreover, they exhibited good pharmacokinetics properties. Accordingly, the outcomes of the present investigations can provide important direction for the development of new anti-Alzheimer's drug candidates.

25 June 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MKMeriem Khedraoui
Meriem Khedraoui
OAOussama ABCHIR
Oussama ABCHIR
HNHASSAN NOUR
HASSAN NOUR
Imane YamariImane Yamari
Imane Yamari
AEAbdelkbir ERROUGUI
Abdelkbir ERROUGUI
SCSamir Chtita
Samir Chtita
Acetylcholinesterase (AChE) is one of the main drug targets for treating Alzheimer’s disease. This current study relies on multiple molecular modeling approaches to develop new potent inhibitors of AChE. We explored a 2D QSAR study using the statistical method of multiple linear regression based on a set of substituted 5-phenyl-1,3,4-oxadiazole and N-benzylpiperidine analogs, which were recently synthesized and proved their inhibitory activities against acetylcholinesterase (AChE). The molecular descriptors, polar surface area, dipole moment, and molecular weight are the key structural properties governing AChE inhibition activity. The MLR model was selected based on its statistical parameters: R2 = 0.701, R2test = 0.76, Q2CV = 0.638, and RMSE = 0.336, demonstrating its predictive reliability. Randomization tests, VIF tests, and applicability domain tests were adopted to verify the model’s robustness. As a result, 11 new molecules were designed with higher anti-Alzheimer’s activities than the model molecule. We demonstrated their improved pharmacokinetic properties through an in silico ADMET study. A molecular docking study was conducted to explore their AChE inhibition mechanisms and binding affinities in the active site. The binding scores of compounds M1, M2, and M6 were (−12.6 kcal/mol), (−13 kcal/mol), and (−12.4 kcal/mol), respectively, which are higher than the standard inhibitor Donepezil with a binding score of (−10.8 kcal/mol). Molecular dynamics simulations over 100 ns were used to validate the molecular docking results, indicating that compounds M1 and M2 remain stable in the active site, confirming their potential as promising anti-AChE inhibitors.

19 February 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
OAOussama ABCHIR
Oussama ABCHIR
MKMeriem Khedraoui
Meriem Khedraoui
HNHassan Nour
Hassan Nour
Imane YamariImane Yamari
Imane Yamari
AEAbdelkbir ERROUGUI
Abdelkbir ERROUGUI
SCSamir Chtita
Samir Chtita
In response to the increasing prevalence of diabetes mellitus and the limitations associated with the current treatments, there is a growing need to develop novel medications for this disease. This study is focused on creating new compounds that exhibit a strong inhibition of alpha-glucosidase, which is a pivotal enzyme in diabetes control. A set of 33 triazole derivatives underwent an extensive QSAR analysis, aiming to identify the key factors influencing their inhibitory activity against α-glucosidase. Using the multiple linear regression (MLR) model, seven promising compounds were designed as potential drugs. Molecular docking and dynamics simulations were employed to shed light on the mode of interaction between the ligands and the target, and the stability of the obtained complexes. Furthermore, the pharmacokinetic properties of the designed compounds were assessed to predict their behavior in the human body. The binding free energy was also calculated using MMGBSA method and revealed favorable thermodynamic properties. The results highlighted three novel compounds with high biological activity, strong binding affinity to the target enzyme, and suitability for oral administration. These results offer interesting prospects for the development of effective and well-tolerated medications against diabetes mellitus.

18 March 2024 in Journal of Molecular Structure
Verified
Journal Article
Closed access
NBNajoua Barghady
Najoua Barghady
Mohammed CHALKHAMohammed CHALKHA
Mohammed CHALKHA
IYImane Yamari
Imane Yamari
NANoura Aflak
Noura Aflak
OAOussama ABCHIR
Oussama ABCHIR
MYMohamed El Yazidi
Mohamed El Yazidi

14 January 2024 in Plant Physiology and Biochemistry
Verified
Journal Article
Closed access
Mohammed BouhadiMohammed Bouhadi
Mohammed Bouhadi
OAOussama ABCHIR
Oussama ABCHIR
IYImane Yamari
Imane Yamari
AYAmal El Hamsas El Youbi
Amal El Hamsas El Youbi
AAAnas Azgaoui
Anas Azgaoui
HFHassan Fougrach
Hassan Fougrach

13 November 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ABAmal Bouribab
Amal Bouribab
EKEl Mehdi Karim
El Mehdi Karim
MKMeriem Khedraoui
Meriem Khedraoui
OAOussama ABCHIR
Oussama ABCHIR
AEAbdelkbir ERROUGUI
Abdelkbir ERROUGUI
SCSamir Chtita
Samir Chtita
Background: Angiogenesis is a crucial process in the growth and proliferation of cancer, enabling tumor growth through the formation of new vasculature and the supply of nutrients and oxygen to growing malignant cells. This disease-promoting process can be targeted through the inhibition of tyrosine kinase enzymes. Objectives: The objective of this study is to evaluate the anticancer potential of various Moroccan plants from different regions. While these plants have a rich history of traditional medicinal use, they have not been extensively investigated as anticancer therapies. Methods: This study employed a multifaceted approach to evaluate the anticancer potential of various Moroccan plants. Receptor–ligand docking and virtual screening were used to assess the binding affinity of phytocompounds to the EGFR and VEGFR2 receptors. Additionally, predictive pharmacokinetic analyses were conducted to evaluate the ADMET properties of the selected compounds, followed by molecular dynamics simulations to analyze the stability of the receptor–ligand complexes. Results: In our research, we identified three notable active compounds—catechin, 4-O-glucoside ferulic acid, and 3-glucoside resveratrol—in the Moroccan plant Ajuga iva L. These findings suggest that Ajuga iva L. may possess significant potential for cancer inhibition. Conclusions: This research highlights the potential of the Moroccan plant Ajuga iva L. as a source of active compounds with significant anticancer properties. Further investigation is essential to validate these findings and explore new therapeutic avenues based on these traditional resources.